Lynsie Conradi is now leukemia free following a groundbreaking new therapy. The news was announced seven days after the new treatment began.
The 23-year-old woman has suffered through three bouts of leukemia. During the second recurrence, doctors discovered the leukemia was resistant to chemotherapy. Without a new treatment plan, Conradi only had a 20 percent chance of survival.
As reported by KOMO News, Conradi was given the opportunity to participate in a study at the Seattle Children’s Hospital. The treatment is called cellular immunotherapy.
Cellular immunotherapy uses the patient’s own blood. T-cells are isolated and treated with a manufactured gene. Dr. Rebecca Gardner, who heads the study, explains how the procedure works:
“That new gene enables the T-cells to recognize the cancer as foreign and bad, and then triggers the T-cell to kill the leukemia cell.”
One week after the treatment Lynsie Conradi’s leukemia is gone. Even the doctors were stunned with the results.
As reported by My Northwest.com, cancer specialist Dr. Doug Hawkins discusses Conradi’s results:
“This is really amazing. I mean this is the sort of result that we wait around all of our careers to see, to see this kind of dramatic response that we couldn’t have hoped for even five or ten years ago.”
Cellular immunotherapy is considered groundbreaking, as it specifically targets the cancer without harsh side-effects associated with other available therapies.
Lynsie Conradi is leukemia free. However, she will soon receive stem cell transplant. The transplant is expected to completely remove any remaining cancer from her body.
The cellular immunotherapy study is currently concentrated on patients suffering from acute lymphoblastic leukemia, which is especially aggressive. They hope the therapy will eventually be used on other forms of cancer.
As reported by Q13Fox.com, Seattle Children’s Cancer and Blood Disorders Center is currently accepting study participants between the ages of 18 and 26. Participants must suffer from relapsed acute lymphoblastic leukemia. Additionally, they must be resistant to chemotherapy and have less than 20 percent chance of survival.
Lynsie Conradi’s leukemia has responded amazingly well to the treatment. She and her family remain positive about the future.